US FDA sets 18 Dec for GSK/Theravance COPD drug Anoro Ellipta
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review the new drug application (NDA) submitted by GlaxoSmithKline and its US partner Theravance for Anoro Ellipta, formally known as UMEC/VI, as a treatment for patients with chronic obstructive pulmonary disease (COPD).